Active Ingredient: Efbemalenograstim alfa
Efbemalenograstim alfa is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
For this indication, competent medicine agencies globally authorize below treatments:
For:
Subcutaneous, 20 milligrams efbemalenograstim alfa, one dose.
One 20 mg dose of efbemalenograstim alfa is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
Efbemalenograstim alfa should be administered at least 14 days before the next dose of chemotherapy. Concomitant use with chemotherapy (i.e. administration on the same day) has been shown to potentiate myelosuppression.
The injections should be given into the thigh, abdomen, buttock or upper arm.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
